Skip to main content

Table 1 Clinical characteristics of enrolled subjects

From: Circulating microRNA-92a level predicts acute coronary syndrome in diabetic patients with coronary heart disease

Variables CHD controls (n = 68) CACS (n = 40) DACS (n = 40) P value
Age, year 47 (44, 52) 52.5 (49.5, 57) 52.5 (50, 57) 0.964
Sex, male % 47 (69.12) 24 (60.00) 32 (80.00) 0.150
BMI, kg/m2 20.68 (19.90, 21.47) 20.23 (19.35, 21.12) 20.96 (19.92, 21.66) 0.046
Smoking Index 410 (215, 565) 420 (210, 790) 460 (200, 740) 0.645
Hemodynamics
 SBP, mmHg 112 (102.5, 119) 123 (117, 131)** 134.5 (124, 154.5)**, † <0.001
 DBP, mmHg 74 (69, 81) 79.5 (71.5, 84) 80 (75, 90)* 0.003
Coagulation Function
 FIB, g/L 2.55 (2.34, 2.91) 2.81 (2.53, 3.07) 3.18 (2.69, 3.67)** <0.001
 D-dimer,µg/L 228.210 (120.86, 303.89) 339.20 (224.65, 491.81)** 333.40 (265.21, 417.22) <0.001
Myocardial Marker
 cTn, ng/ml 0.03 (0.02, 0.04) 0.02 (0.01, 0.03) 0.05 (0.01, 3.07) † 0.010
Blood Glucose
 RBG, mmol/L 4.86 (4.42, 5.37) 9.02 (6.58, 12.16)** 11.51 (8.30, 14.39)**, † <0.001
 HbA1C, % 4.68 (4.47, 4.94) 5.35 (4.78, 5.86)** 8.00 (7.27, 9.60)**, †† <0.001
Blood Lipids
 LDL-C, mmol/L 2.66 (2.42, 2.89) 3.11 (2.63, 3.92)** 2.61 (2.15, 3.39)† <0.001
 TG, mmol/L 1.04 (0.77, 1.34) 1.48 (0.85, 2.37) ** 1.59 (0.95, 3.40) ** <0.001
 TC, mmol/L 3.98 (2.04, 4.76) 4.84 (4.26, 5.42)** 4.56 (3.26, 6.27)* <0.001
 HDL-C, mmol/L 0.70 (0.41, 1.01) 1.04 (0.87, 1.32)** 0.92 (0.55, 1.19) <0.001
Biomarkers
 miR-92aa 2.39 (1.03) 3.88 (0.78)** 5.60 (1.22)**,†† <0.001
Treatment antiplatelet therapy (81.16%), nitrates (43.49%), ACEI/ARB (75.36%), statins (79.71%), beta-blockers (40.58%) antiplatelet therapy (90.00%), nitrates (85.71%), ACEI/ARB (72.86%), statins (88.57%), beta-blockers (54.29%), diuretics (62.86%) antiplatelet therapy (81.20%), nitrates (70.09%), ACEI/ARB (87.18%), statins (95.73%), beta-blockers (29.91%), biguanides (24.79%), insulins (41.88%)  
  1. #All the continuous variables were compared using Kruskal-Wallis analysis and presented by median (interquartile range) for their non-normal distribution unless there are some additional notes such as a. One-way analysis of variance was adopted to evaluate the equality of marked indicator, which was presented by average (standard deviation). *P < 0.017, **P < 0.001 vs. NC group; †P < 0.017, ††P < 0.001 vs. CACS group.